Cargando…

The mixed benefit of low lipoprotein(a) in type 2 diabetes

BACKGROUND: Lipoprotein(a) (Lp(a)), a variant low-density lipoprotein (LDL), is a major genetic risk factor for cardiovascular disease. It is unknown whether an inverse relationship exists between Lp(a) and β-cell function (BCF), as for LDL-cholesterol (LDL-C) lowering by statins. We therefore asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermans, Michel P., Ahn, Sylvie A., Rousseau, Michel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596924/ https://www.ncbi.nlm.nih.gov/pubmed/28899393 http://dx.doi.org/10.1186/s12944-017-0564-9

Ejemplares similares

Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids
por: Hermans, Michel P, et al.
Publicado: (2014)

The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females
por: Hermans, Michel P, et al.
Publicado: (2012)

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
por: Hermans, Michel P, et al.
Publicado: (2010)

Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B(100) in patients with T2DM
por: Hermans, Michel P, et al.
Publicado: (2013)

Non-HDL-cholesterol as valid surrogate to apolipoprotein B(100 )measurement in diabetes: Discriminant Ratio and unbiased equivalence
por: Hermans, Michel P, et al.
Publicado: (2011)

Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
por: Hermans, Michel P., et al.
Publicado: (2015)

Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
por: Kim, Hyun‐Ki, et al.
Publicado: (2022)

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
por: Hermans, Michel P.
Publicado: (2010)

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes
por: Lurquin, Fabian, et al.
Publicado: (2023)

Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure
por: Gruson, Damien, et al.
Publicado: (2021)

Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysis
por: CHRISTIAENS, Antoine, et al.
Publicado: (2019)

Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes: The OPTIMISE randomized, controlled trial
por: Hermans, Michel P., et al.
Publicado: (2013)

Small Dense Low-Density Lipoprotein Level in Newly Diagnosed Type 2 Diabetes Mellitus Patients With Normal Low-Density Lipoprotein
por: Juhi, Ayesha, et al.
Publicado: (2023)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
por: Bays, Harold E
Publicado: (2014)

Lipoprotein particle sizes and incident type 2 diabetes: the PREVEND cohort study
por: Sokooti, Sara, et al.
Publicado: (2021)

Duration of Type 2 Diabetes and Very Low Density Lipoprotein Levels Are Associated with Cognitive Dysfunction in Metabolic Syndrome
por: Yogi-Morren, Divya, et al.
Publicado: (2014)

C-reactive protein is associated with low-density lipoprotein cholesterol and obesity in type 2 diabetic Sudanese
por: Dongway, Angelo C, et al.
Publicado: (2015)

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes
por: Hayashi, Toshiyuki, et al.
Publicado: (2023)

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol
por: Fonseca, Liliana, et al.
Publicado: (2020)

Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus
por: Nobels, Frank, et al.
Publicado: (2011)

Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes
por: Kamijo, Yuka, et al.
Publicado: (2019)

Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients
por: Thongtang, Nuntakorn, et al.
Publicado: (2017)

A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients
por: Binet, Quentin, et al.
Publicado: (2023)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
por: Colhoun, Helen M., et al.
Publicado: (2020)

Mixed Modeling of Meta-Analysis P-Values (MixMAP) Suggests Multiple Novel Gene Loci for Low Density Lipoprotein Cholesterol
por: Foulkes, Andrea S., et al.
Publicado: (2013)

Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results
por: Vavere, Andrea L., et al.
Publicado: (2023)

Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes
por: Lotta, Luca A., et al.
Publicado: (2018)

Low Density Lipoprotein Cholesterol Target Goal Attainment Rate in Korean Patients with Diabetes
por: Lee, Eun Hae, et al.
Publicado: (2011)

A comparative study of antioxidant potential of low density lipoprotein in type 2 diabetic men and women
por: Singh, Nivedita, et al.
Publicado: (2012)

Elevation of small, dense low density lipoprotein cholesterol—a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos, North-Central Nigeria
por: Inaku, Kenneth O., et al.
Publicado: (2017)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Lipoprotein(a) Concentrations Correlate With LDL-C in Children With Type 1 and 2 Diabetes
por: Foster, Christy, et al.
Publicado: (2021)

Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men
por: Nour Eldin, Essam Eldin Mohamed, et al.
Publicado: (2014)

La proteína de unión a los ácidos grasos cardíaca (HFABP) está relacionada con la gravedad de la insuficiencia cardíaca y sus biomarcadores cardíacos conocidos
por: Gruson, Damien, et al.
Publicado: (2021)

High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity
por: Denimal, Damien, et al.
Publicado: (2023)

Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease
por: Orekhov, Alexander N., et al.
Publicado: (2014)

Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes
por: Yu, Jie, et al.
Publicado: (2013)

Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
por: Bando, Yukihiro, et al.
Publicado: (2016)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7s59f2t1dsg1avqbammed29b6g